Exploring Nitric Oxide (NO)-Releasing Celecoxib Derivatives as Modulators of Radioresponse in Pheochromocytoma Cells
COX-2 can be considered as a clinically relevant molecular target for adjuvant, in particular radiosensitizing treatments. In this regard, using selective COX-2 inhibitors, e.g., in combination with radiotherapy or endoradiotherapy, represents an interesting treatment option. Based on our own findin...
Main Authors: | Florian Brandt, Martin Ullrich, Verena Seifert, Cathleen Haase-Kohn, Susan Richter, Torsten Kniess, Jens Pietzsch, Markus Laube |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/27/19/6587 |
Similar Items
-
Target therapy in metastatic pheochromocytoma: current perspectives and controversies
by: Amrallah A. Mohammed, et al.
Published: (2014-09-01) -
Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
by: Ying Pang, et al.
Published: (2019-03-01) -
Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine
by: Svenja Nölting, et al.
Published: (2019-10-01) -
Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT
by: Erica S. Tsang, et al.
Published: (2021-07-01) -
Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2α in Pheochromocytoma Cells
by: Nicole Bechmann, et al.
Published: (2019-04-01)